If you only glanced at Granules India through the lens of regulatory worries, peptide overcapacity, and capital intensity, the past year might look like a minefield rather than an opportunity. Holding Granules India over the past year would have returned 49.1%, including dividends. If you had been weighing that decision in November 2025, how much of this outcome was already foreshadowed by the clash between bullish expansion hopes and bearish balance sheet concerns?
If the move has made Granules India harder to judge, start where the gap is still open and scan 196 high quality undervalued stocks.
The shares cost ₹556 at the start of the period, and Granules India sat between two sharply different stories about what came next.
The bullish narrative saw a fair value of ₹700, a price implied by assumptions that revenue could grow 17.6% a year with profit margins reaching 13.0% as expanded API, oncology, peptide, and CDMO capacity met rising demand.
The bearish view anchored on a fair value of ₹480, built on concerns that peptide CDMO overcapacity, higher regulatory costs, and elevated debt might restrain earnings even if revenue rose 15.3% a year with 13.1% margins.
The clearest new data point was Granules India’s Q2 2027 report. Revenue moved from ₹12,969.88m in Q2 2026 to ₹15,599.74m, while net income rose from ₹1,306.06m to ₹1,818.37m. Net margin shifted from 10.1% to 11.7%. That combination of higher sales and a thicker margin gave more weight to the optimistic case, although only over one quarter.
The key lesson is simple. When a thesis hinges on margin expansion, keep checking reported net margin against the original story rather than only watching revenue or the share price.
Granules India now trades at ₹814 after a 49.1% gain over the past year, while the bearish analyst narrative on Simply Wall St places its Fair Value below that level. The gap reflects concern that cost pressure, remediation spending and peptide volatility could limit how much operating leverage actually shows up.
For today’s valuation to hold, a buyer needs to believe Granules India can keep lifting complex generics and peptide CDMO contribution without cost inflation, uneven project mix or ongoing remediation costs capping margins and cash generation.
"The main thing that has to go right is that Granules India converts its higher mix of complex generics, peptide CDMO build out and broader US and European reach into durable margins around guided levels, while containing cost inflation and execution setbacks."
Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there
You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.
Three companies from the same screener. Open the full list of 198 financially solid companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com